Open AccessCD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma
Author(s) -
Liqun Zhou,
Yanzhi Feng,
Piao Li,
Shennan Wang,
Xinyue Liu,
Shu Xia
Publication year - 2022
Publication title -
international journal of general medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.722
H-Index - 36
ISSN - 1178-7074
DOI - 10.2147/ijgm.s352851
Subject(s) - medicine , biomarker , adenocarcinoma , immunity , lung , cancer research , lung cancer , oncology , immunology , cancer , immune system , biology , genetics
Tumor mutation burden (TMB) and tumor-infiltrating lymphocytes (TILs) have been well recognized as molecular determinants of immunotherapy responsiveness. In this study, we aimed to construct a TMB prognostic model and explore biomarkers that have predictive potential for prognosis and therapeutic effect in lung adenocarcinoma (LUAD).